On Tuesday, NeoStem Inc (NASDAQ:NBS)’s shares declined -12.77% to $2.46.
NeoStem Inc (NBS) declared that the Company’s administration and experts will present at multiple conferences in May and early June.
World Stem Cells and Regenerative Medicine Congress
Date and Time: Wednesday, May 20, 2015, 3:30 PM GMT
Venue: Business Design Centre, London
Website: http://www.terrapinn.com/conference/stem-cells/
Presenter: Dr. Robert Preti, President of PCT, Chief Scientific Officer of NeoStem
Topic: Accelerating Time To Market: Development and manufacturing considerations for cell therapy product commercialization.
NeoStem, Inc., a clinical-stage biopharmaceutical company, develops cell based therapeutics in the United States. It is developing NBS20, a targeted cancer immunotherapy product that is in Phase III clinical trials for the treatment of metastatic melanoma; NBS10, a ischemic repair product that is in Phase II clinical trial to preserve heart muscle function following an acute myocardial infarction; and NBS03D, an immune modulation product that is in Phase II clinical trials for the treatment of type 1 diabetes.
PTC Therapeutics, Inc. (NASDAQ:PTCT)’s shares dropped -12.67% to $53.13.
PTC Therapeutics, Inc. (PTCT) declared that its oncology program targeting BMI1, a protein linked to drug-resistant cancers, has entered a Phase 1 study in patients with advanced solid tumors. The open-label, first-in-human study will investigate the safety and pharmacokinetics of PTC596, an orally accessible small molecule. PTC’s BMI1 program is supported by a partnership with the Wellcome Trust.
BMI1 has been implicated in a wide variety of cancers and has been demonstrated to contribute to therapeutic resistance and treatment failure. BMI1 is thought to play a role in the survival and maintenance of tumor stem cells in many cancers, counting central nervous system cancers such as glioblastoma. Elevated levels of BMI1 have been associated with advanced tumor grade and a poor prognosis.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes.
At the end of Tuesday’s trade, Molycorp Inc (NYSE:MCP)‘s shares dipped -10.11% to $0.800.
Molycorp Inc (MCP) to supply rare earth materials over the next 10 years from its Mountain Pass, California facility for incorporation into Siemens’ high-efficiency, direct drive wind turbine generators. Molycorp will supply rare earth materials to Shin-Etsu Chemical Co., Ltd. (“Shin-Etsu”), which will produce the rare earth magnets Siemens intends to utilize in its wind turbines.
Siemens officials noted that key factors in choosing Molycorp were Molycorp’s ability to provide greater global diversification and reliability to its supply chain, in addition to the environmental and process innovations Molycorp has built into its Mountain Pass rare earth facility. Among those innovations are the facility’s ability to recycle water, regenerate the chemical reagents needed in rare earth production, generate power from a high-efficiency natural gas cogeneration power plant, and dispose of mine tailings through an innovative paste tailings system.
Molycorp, Inc. produces and sells rare earths and rare metal materials in the United States and internationally. The company’s Resources segment extracts rare earth minerals, counting light rare earth concentrates; rare earth oxides (REO), such as lanthanum, cerium, and neodymium-praseodymium; heavy rare earth concentrates, which comprise samarium, europium, gadolinium, terbium, dysprosium, and others; and SorbX and PhosFIX, a line of rare earth-based water treatment products. This segment’s products are used in oil refinery catalyst, glass polishing, automotive and emission catalysts, water purification, and energy efficiency lighting applications.
FreightCar America, Inc. (NASDAQ:RAIL), ended its Tuesday’s trading session with -9.89% loss, and closed at $25.24.
FreightCar America, Inc. (RAIL) stated results for the first quarter ended March 31, 2015, with revenues of $92.8 million and a net loss of $2.1 million, or $(0.17) per diluted share. For the first quarter of 2014, the Company stated revenues of $56.1 million and a net loss of $6.9 million, or $(0.58) per diluted share. Revenues were $212.5 million with net income of $4.8 million, or $0.39 per diluted share, in the fourth quarter of 2014.
FreightCar America, Inc., through its auxiliaries, designs, manufactures, and sells aluminum-bodied railcars and coal cars that transport various non-liquid commodities and products primarily in North America.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
